How To Reduce Prostate Symptoms

8629 Views
Was this article interesting to you?
Posted in: Prostate

Scientific Sources

How common are prostate symptoms in men over 40?

Between ages 40-49, about 25% men suffer lower urinary tract symptoms from progressive prostate enlargement. At 70-79 years, more than 80% suffer these symptoms. Dramatic age-related increase in BPH prevalence.

What percentage of men in their 50s have BPH?

Up to 42% of men in their 50s or older have BPH. Estimates of men aged 70-79 with BPH who have discernible lower urinary tract symptoms are greater than 80%. Progressive enlargement with age.

Are BPH and erectile dysfunction related conditions?

BPH with resulting LUTS often accompanied by erectile dysfunction. Increasing evidence that BPH/LUTS and ED have common features and may be related problems. Epidemiological studies suggest BPH/LUTS risk factor for ED.

Do BPH medications cause sexual side effects?

Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life reviewed. Pharmaceutical BPH treatments (alpha-blockers, 5-alpha reductase inhibitors) causing erectile dysfunction, decreased libido, ejaculatory disorders. Natural alternatives needed.

Can flower pollen extract help reduce prostate symptoms?

Critical review of Graminex flower pollen extract for symptomatic relief of lower urinary tract symptoms in men. Natural intervention reducing LUTS without sexual side effects of pharmaceutical treatments. Prostate support validated.

  • Affects 25% of men aged 40-49 early intervention crucial
  • Impacts over 80% of men over 70 virtually universal with age
  • Reduces urinary frequency fewer daytime bathroom trips
  • Improves nighttime sleep by reducing nocturia episodes
  • Strengthens urinary stream better bladder emptying
  • Reduces urgency sensations more control and comfort
  • Prevents complications like urinary retention and infections
  • Often linked with ED shared underlying causes
  • Can be addressed together integrated treatment approach
  • Natural alternatives available without sexual side effects
  • Flower pollen extract effective clinically validated relief
  • Avoids drug side effects no retrograde ejaculation
  • Preserves sexual function unlike pharmaceutical options
  • Reduces prostate inflammation addressing root cause
  • Improves quality of life less anxiety about symptoms
  • Safe for long-term use natural intervention approach
  • Works through multiple mechanisms anti-inflammatory and hormonal
  • Helps preserve relationships addressing both urinary and sexual health

Prostate Symptom Reduction Protocol

Step 1: 25% Men 40-49 Rising to 80% Over 70 - Progressive BPH

Between ages 40-49, about 25% men suffer lower urinary tract symptoms (LUTS) from progressive prostate enlargement benign prostatic hyperplasia (BPH). At 70-79 years, more than 80% suffer these symptoms. Dramatic age-related increase - one quarter middle-aged men, overwhelming majority elderly men. Progressive enlargement virtually inevitable with aging - prostate continues growing throughout adult life under hormonal influence (dihydrotestosterone DHT). LUTS symptoms: urinary frequency (urinating more than 8 times daily), urgency (sudden strong urge), nocturia (nighttime urination disrupting sleep 2+ times), weak stream, hesitancy, incomplete emptying, post-void dribbling. Quality of life significantly impacted - sleep disruption, social embarrassment, anxiety about finding restrooms, interference with activities, travel limitations.

Step 2: 42% Men 50s BPH, Greater 80% Aged 70-79 with LUTS

Up to 42% of men in their 50s or older have BPH diagnosis. Estimates of men aged 70-79 with BPH who have discernible lower urinary tract symptoms are greater than 80% - nearly universal problem in elderly men. BPH prevalence increasing steadily with age: 50s (42%), 60s (60-70%), 70s (80%+). Not all BPH causes symptoms - some men have enlarged prostate without LUTS (asymptomatic BPH), others have symptoms proportional or disproportional to size. LUTS severity assessed by International Prostate Symptom Score (IPSS) questionnaire: mild (0-7 points), moderate (8-19), severe (20-35). Natural history: symptoms progressively worsen without intervention, complications develop (acute urinary retention, bladder damage, kidney problems, urinary tract infections, bladder stones). Early intervention preventing progression to complications.

Step 3: BPH/LUTS and Erectile Dysfunction - Related Problems Common Features

BPH with resulting LUTS often accompanied by erectile dysfunction (ED). Increasing evidence that BPH/LUTS and ED have common features and may be related problems beyond coincidental age-related occurrence. Epidemiological studies suggest BPH/LUTS is risk factor for ED - men with moderate-to-severe LUTS having 2-3 times higher ED prevalence than men without LUTS. Shared pathophysiological mechanisms: endothelial dysfunction (affecting blood flow to both prostate and penis), nitric oxide pathway impairment, chronic inflammation, autonomic nervous system dysfunction, metabolic syndrome (obesity, diabetes, dyslipidemia affecting both conditions). Treating BPH may improve ED and vice versa - addressing underlying vascular, metabolic, inflammatory factors benefiting both. Integrated approach to male aging addressing multiple interconnected conditions simultaneously.

Step 4: Medical Therapy Sexual Dysfunction - Quality of Life Impact

Medical therapy for benign prostatic hyperplasia reviewed regarding sexual dysfunction and impact on quality of life. Pharmaceutical BPH treatments causing sexual side effects: alpha-blockers (tamsulosin, alfuzosin - improving urine flow by relaxing prostate/bladder neck smooth muscle) causing retrograde ejaculation (semen going into bladder instead of out penis) in 5-10%, dizziness, hypotension. 5-alpha reductase inhibitors (finasteride, dutasteride - shrinking prostate by blocking DHT conversion) causing erectile dysfunction (15-20%), decreased libido (10%), ejaculatory disorders (7-8%), potentially irreversible even after discontinuation ("post-finasteride syndrome"). Combination therapy (alpha-blocker plus 5ARI) higher sexual side effect rates. Quality of life impact - men choosing between urinary symptom relief versus sexual function preservation. Natural alternatives needed providing LUTS relief without sexual side effects for men unwilling to sacrifice sexual health.

Step 5: Graminex Flower Pollen Extract - Natural LUTS Symptomatic Relief

Critical review of Graminex flower pollen extract for symptomatic relief of lower urinary tract symptoms in men. Natural intervention reducing LUTS without sexual side effects of pharmaceutical treatments. Flower pollen extract (specific proprietary preparation from rye grass pollen) showing clinical benefits: reduced nocturia (nighttime urination episodes decreasing), improved urinary flow rate, reduced residual urine volume, decreased prostate inflammation. Mechanisms: anti-inflammatory effects (reducing prostatic inflammation contributing to obstruction), 5-alpha reductase inhibition (mild DHT reduction without sexual side effects), smooth muscle relaxation, antioxidant protection. Clinical studies showing LUTS improvement comparable to prescription medications but without sexual dysfunction, hypotension, other side effects. Prostate support validated through multiple controlled trials. Dosage typically 60-120 mg twice daily. Safe long-term use. Additional benefits: general anti-inflammatory effects, antioxidant properties, potential fertility benefits (used in male infertility).

Step 6: Comprehensive Prostate Symptom Reduction Strategy

Lower urinary tract symptoms from progressive prostate enlargement affecting 25% men ages 40-49, rising dramatically to over 80% men aged 70-79. Up to 42% men in 50s have BPH with greater than 80% aged 70-79 having discernible LUTS requiring intervention. BPH/LUTS often accompanied by erectile dysfunction - related problems sharing common pathophysiological mechanisms (endothelial dysfunction, inflammation, metabolic syndrome). Medical therapy for BPH causing sexual dysfunction and quality of life impact - alpha-blockers causing retrograde ejaculation, 5-alpha reductase inhibitors causing ED and decreased libido. Graminex flower pollen extract providing natural symptomatic relief of LUTS without sexual side effects - validated prostate support through anti-inflammatory, mild DHT inhibition, smooth muscle relaxation mechanisms addressing age-related prostate enlargement preserving sexual function quality of life.

  • Men 40-49 early symptoms
  • Men over 70 high prevalence
  • BPH diagnosis confirmed
  • LUTS symptoms urinary frequency
  • Erectile dysfunction associated
  • Prostate cancer (different condition)
  • Urinary tract infection active

LUTS Secondary to BPH with Erectile Dysfunction - Asian Men Systematic Review: Between ages 40-49, about 25% men suffer lower urinary tract symptoms from progressive prostate enlargement BPH. At 70-79 years, more than 80% suffer. Up to 42% men in 50s or older have BPH with discernible LUTS greater than 80% aged 70-79. BPH with LUTS often accompanied by erectile dysfunction. Systematic review establishing high prevalence progressive nature requiring interventions for symptom relief and quality of life.

Citation: Park HJ, Won JE, Sorsaburu S, Rivera PD, Lee SW. Urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and LUTS/BPH with erectile dysfunction in Asian men: a systematic review. World J Mens Health. Systematic review establishing 25%-80% age-related BPH/LUTS prevalence with ED association.

BPH Epidemiology Associated Risks Management - German Men Over 50: Epidemiology of benign prostatic syndrome with associated risks and management data in German men over age 50. Progressive prostate enlargement affecting majority older men. Risk factors, natural history, management options reviewed for aging male population requiring symptom management interventions.

Citation: Berges R. Epidemiology of benign prostatic syndrome. Associated risks and management data in German men over age 50. Urologe A. 2008 Feb;47(2):141-8. German epidemiological study establishing BPH prevalence management in aging men.